3 Firms Help Blueprint Medicine Get $1.25B Investment
Life science investors Sixth Street and Royalty Pharma announced Thursday they would invest up to $1.25 billion in Blueprint Medicines Corp. to expand commercial opportunities for two drugs that treat certain...To view the full article, register now.
Already a subscriber? Click here to view full article